NMRA Key Statistics, Chart & Performance
The current stock price of NMRA is 1.78 USD. In the past month the price decreased by -22.27%. In the past year, price decreased by -84.29%.
NMRA Latest News, Press Relases and Analysis
NMRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About NMRA
Company Profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Company Info
NEUMORA THERAPEUTICS INC
260 Arsenal Place, Suite 1
Watertown MASSACHUSETTS US
Employees: 95
Phone: 18577600900
NEUMORA THERAPEUTICS INC / NMRA FAQ
What does NMRA do?
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
What is the current price of NMRA stock?
The current stock price of NMRA is 1.78 USD. The price decreased by -1.66% in the last trading session.
What is the dividend status of NEUMORA THERAPEUTICS INC?
NMRA does not pay a dividend.
What is the ChartMill rating of NEUMORA THERAPEUTICS INC stock?
NMRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for NMRA stock?
14 analysts have analysed NMRA and the average price target is 9.35 USD. This implies a price increase of 425.28% is expected in the next year compared to the current price of 1.78.
What is the GICS sector and industry of NMRA stock?
NEUMORA THERAPEUTICS INC (NMRA) operates in the Health Care sector and the Pharmaceuticals industry.
What is NEUMORA THERAPEUTICS INC worth?
NEUMORA THERAPEUTICS INC (NMRA) has a market capitalization of 293.33M USD. This makes NMRA a Micro Cap stock.
NMRA Technical Analysis
NMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRA. The financial health of NMRA is average, but there are quite some concerns on its profitability.
NMRA Financial Highlights
Over the last trailing twelve months NMRA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 22.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.88% | ||
| ROE | -178.79% | ||
| Debt/Equity | 0.15 |
NMRA Forecast & Estimates
14 analysts have analysed NMRA and the average price target is 9.35 USD. This implies a price increase of 425.28% is expected in the next year compared to the current price of 1.78.